查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466102

勝胜肽治療市場：按技術、藥物類別、給藥途徑、應用、最終用戶、製造類型分類 - 2024-2030 年全球預測

Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Adrenocorticotropic Hormone, Calcitonin, Insulin), Route of Administration, Application, End User, Manufacturing Type - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年勝胜肽治療市場規模為330.6億美元，預計2024年將達357.6億美元，2030年將達579.7億美元，複合年成長率為8.35%。

胜肽療法使用短鏈氨基酸來治療或控制多種疾病和病症。這些生物活性分子具有獨特的性質，使其成為高效能藥物開發和藥物研究的選擇。包括癌症和糖尿病在內的慢性疾病的擴散增加了對有效治療方案的需求，以及更好地了解蛋白質-蛋白質相互作用以實現標靶治療。由於研發活動投資增加以及治療候選藥物臨床管道不斷增加，新型胜肽療法正在開發中。然而，胜肽固有的不穩定性和高製造成本會對勝胜肽療法的開發產生負面影響。此外，藥物輸送系統的最新進展和新勝胜肽的開發預計將擴大胜肽的潛在應用。

主要市場統計
基準年[2023] 330.6億美元
預測年份 [2024] 357.6億美元
預測年份 [2030] 579.7億美元
複合年成長率（%） 8.35%

技術：在複雜勝胜肽的合成中增加固相方法的利用率

混合相方法結合了液相和固相合成的特徵，以提高效率和可擴展性，同時保持勝胜肽生產的高純度水平。該方法是開發複雜或胜肽的首選方法，胜肽它克服了與傳統方法相關的挑戰。液相胜肽合成 (LPPS) 使用各種化學反應將溶液中的胺基酸結合。與固相方法相比，LPPS具有相對較快的反應速率，使其適合短鏈至中鏈勝胜肽的小規模生產。固相勝胜肽合成 (SPPS) 涉及將第一個胺基酸連接到固體樹脂支撐物上，然後依序添加後續胺基酸。這種方法受到廣泛的青睞，因為它可以合成更長、更複雜的胜肽，更容易精製，並且可擴展。混合相技術結合了胜肽。溶液相合成主要用於短鏈至中鏈勝胜肽的小規模生產。固相勝胜肽合成受到廣泛青睞，因為它提供了一種易於精製和規模化的選擇，同時提供了合成更長、更複雜勝胜肽的多功能性。

藥物類別：第 1 型和第 2 型糖尿病患者對胰島素調節葡萄糖代謝的需求不斷增加

促腎上腺皮質激素（ACTH）是一種由腦下垂體前葉分泌和產生的多肽激素。在治療上，促腎上腺皮質激素用於治療某些需要刺激皮質醇產生的疾病。這包括治療對皮質醇水平升高有反應的疾病，例如腎上腺功能不全和某些發炎疾病。治療時使用的外源性製劑直接刺激腎上腺皮質，模擬ACTH的作用發生，刺激皮質醇的分泌，進而發揮發炎和活化作用。抑鈣素在鈣和磷代謝中很重要。在人類中，它主要由甲狀腺濾泡旁細胞產生。鮭魚衍生或合成的抑鈣素的治療形式主要用於治療停經後骨質疏鬆症、佩吉特氏症和高鈣血症。透過抑制破骨細胞活性，抑鈣素可抑制骨吸收並降低血鈣濃度。胰島素是一種基本的肽激素，對於調節胰臟BETA細胞產生的葡萄糖代謝非常重要，促進肌肉、肝臟和脂肪細胞從血液中攝取葡萄糖。在治療方面，胰島素對於第 1 型和第 2 型糖尿病的治療至關重要。亮丙瑞林是促性腺激素分泌釋放激素 (GnRH) 的合成類似物，連續給藥時可充當有效的促性腺激素分泌分泌抑制劑。它用於治療荷爾蒙反應性癌症，例如男性前列腺癌和女性子宮內膜異位症和子宮肌瘤。Octreotide是天然荷爾蒙生長抑制素的合成胜肽類似物，具有相似但更持久的藥理作用。Octreotide主要用於治療肢端肥大症，其特徵是生長激素分泌過多，這是由某些類型的激素分泌腫瘤引起的疾病，例如類癌和血管活性腸胜肽分泌腺瘤（VIP腫瘤）。Octreotide透過抑制多種荷爾蒙的分泌來發揮作用，包括生長激素、胃泌素、胰島素和升糖素。加壓素，也稱為抗利尿激素（ADH），是肽激素。 ADH 透過增加腎臟集合管中的水分重吸收來調節體內的水分儲存。在治療上，增壓素及其類似物用於治療糖尿病性腎衰竭（其特徵是過度乾燥和產生大量稀尿），並由於其血管收縮作用而用於治療靜脈曲張出血。

給藥途徑：靜脈注射由於其即時效果和有效性而擴大在急診醫院中使用。

胜肽療法的靜脈注射直接進入血液，促進即時生物有效性。此途徑對於胃腸道吸收較差或經由其他途徑給藥時容易代謝的勝胜肽特別有利。靜脈注射對於用於急診護理或胜肽快速起效的勝胜肽至關重要。然而，管理需要臨床基礎設施和熟練的工作人員，這可能會限制其對門診病人和慢性治療的適用性。鼻腔和肺部給藥為勝胜肽治療提供了一種非侵入性給藥方法，可以有效吸收並針對特定症狀立即起效。鼻腔給藥特別適合利用鼻-腦途徑標靶中樞神經系統的胜肽。肺部給藥是針對呼吸系統疾病的胜肽的理想選擇，可以直接輸送到肺部。這兩種方法都繞過首過代謝，因此有可能提高治療的生物有效性。口服給藥因其方便性、患者依從性和成本效益而成為首選的給藥途徑。胜肽在胃腸道中容易被酵素分解，且穿過腸上皮的滲透性較低。酵素抑制劑、滲透增強劑和奈米顆粒遞送系統等製藥科學的進步，為在不同程度上克服這些障礙提供了潛力。勝胜肽療法的經皮給藥不需要注射或特殊的吸入裝置，因此描述了療效和患者依從性之間令人信服的平衡。此途徑對於需要緩釋性藥物釋放的慢性疾病特別有利。微針、離子電滲透療法和超音波等經皮技術的進步改善了胜肽穿過皮膚屏障的轉運。增強皮膚滲透性和胜肽穩定性的製劑策略是經皮製劑成功開發的核心。

應用：擴大胜肽療法在循環系統疾病的應用，模擬內源性胜肽參與血壓調節的作用

在循環系統疾病中，胜肽療法已被使用，因為其精確的作用機制使其能夠有效調節血管功能、血壓和凝血途徑。抗凝血胜肽用於預防血栓症，血栓形成是心肌梗塞和中風的重要危險因子。對於胃腸道 (GI) 疾病，胜肽療法提供了一種標靶治療選擇。此外，模擬或抑制胃腸激素的勝胜肽可以調節胃腸道內的運動、吸收和分泌，並解決各種疾病的症狀。其有針對性的行動可以幫助控制荷爾蒙失衡和胃腸道相關疾病破壞引起的症狀。胜肽療法為傳染病的治療帶來了一種新方法，尤其是在抗生素抗藥性日益增強的時代。胜肽(AMP) 具有廣泛的抗菌活性，可透過破壞某些細菌、真菌甚至病毒的細胞膜來作用於它們。其作用機制降低了產生抗藥性細菌的可能性，使其成為對抗抗藥性感染疾病的重要候選者。在神經系統疾病中，正在研究穿透血腦障壁（BBB）並直接對中樞神經系統（CNS）發揮神經保護作用的可能性。勝胜肽針對特定的神經傳導物質系統，為治療阿茲海默症、帕金森氏症和多發性硬化症等疾病提供了機會。在腫瘤學中，勝胜肽治療是一個快速成長的領域，人們正在研究勝胜肽的抗癌特性，包括對癌細胞的直接細胞毒性作用、抑制血管生成以及標靶藥物傳遞的載體。腫瘤歸巢胜肽可以選擇性地將化療藥物和放射性核素遞送至癌細胞，最大限度地減少對健康組織的損害並提高治療效果。

最終使用者：擴大胜肽療法在醫院和診所的使用，以解決和管理病患病情

在醫院和診所，胜肽療法主要用於直接患者治療。它用於治療許多疾病，包括癌症、代謝失調、心血管疾病和感染疾病。由於其高特異性、有效性和相對低的毒性，胜肽藥物代表了一種標靶治療方法，與傳統的小分子藥物相比，它具有更高的療效和更少的副作用。隨著胜肽工程和藥物傳輸技術的進步，胜肽藥物在醫院和診所的應用不斷發展，提高了其療效和患者依從性。長期照護機構優先考慮確保患者長期健康的治療，通常注重管理而不是治療。長期照護機構使用的胜肽治療必須最大限度地減少副作用，並降低給藥頻率，以適應護理環境。實驗室在胜肽治療開發的早期階段至關重要。研究人員致力於識別新的生物活性勝胜肽，闡明其作用機制，並最佳化其治療用途的特性。為此，我們將利用尖端的分子生物學、生物化學和藥理技術來設計、合成和評估候選勝胜肽的活性。

製造類型：由於專業製造能力和快速擴大生產規模的需要，增加了 CMO 的招聘

受託製造廠商為沒有必要的內部製造設施或選擇外包製造以專注於其核心競爭力的製藥和生物技術公司提供胜肽療法製造的基本服務。 CMO 提供各種服務，從用於研究的小規模胜肽合成到用於商業用途的大規模生產。 CMO 擁有高效能、合規生產勝胜肽治療藥物所需的技術專長、先進技術和監管知識。內部製造是指製藥或生技公司擁有製造勝胜肽療法的設備和資源。這種方法使公司能夠直接控制生產過程、品管和供應鏈管理，從而潛在地降低與依賴外部供應商相關的風險。大型製藥公司有財力投資必要的基礎設施和技術人員，並且通常建立內部生產設施。這種模式有利於研發活動和製造的更緊密整合，這對於快速發展的治療領域是有利的。

區域洞察

在美洲，由於製藥業的成熟、研究活動的增加以及核准胜肽藥物數量的增加，胜肽治療市場正在發展。該地區的專利活動引人注目，多家大型製藥公司的總部均設在該地區。近年來，對創新勝胜肽製劑的投資有所增加，顯示出新治療方法的巨大市場潛力。慢性病盛行率的上升、醫療保健基礎設施的改善以及對勝胜肽治療的認知不斷提高正在推動亞太地區胜肽治療市場的成長。此外，高效、可擴展且具有成本效益的勝胜肽生產合成策略正在取得進展和發展，而胜肽療法的全球普及預計將會增加。由於支持生物技術創新並資助與胜肽治療相關的研究計劃的法律規範，胜肽治療市場正在歐洲、中東和非洲地區發展。歐盟 (EU) 代表了勝胜肽療法的成熟市場，並得到全面的醫療保健系統和對先進治療方案的高度認知的支持。透過歐洲藥品管理局 (EMA) 的歐盟法規結構有助於核准和監控勝胜肽類藥物。由於研究活動的活性化和對先進治療方案認知的提高，非洲地區的胜肽治療市場目前正在穩步成長。

FPNV定位矩陣

FPNV定位矩陣對於評估勝胜肽治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限。最前線 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對勝胜肽治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該細分市場競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、碎片化主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：包括新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：包括對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.胜肽治療市場的市場規模與預測是多少？

2. 在勝胜肽治療市場的預測期內，我們應該考慮投資哪些產品和應用？

3.胜肽治療市場的技術趨勢和法規結構是什麼？

4.胜肽治療市場主要廠商的市場佔有率是多少？

5. 進入勝胜肽治療市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病的流行和有效治療方法的需求
      • 胜肽在美容皮膚科的快速應用
    • 抑制因素
      • 回顧勝胜肽治療的不良反應
    • 機會
      • 持續進行研究和開發活動，在世界各地開發新的勝胜肽
      • 向個人化醫療的轉變和胜肽生物標記的鑑定
    • 任務
      • 勝胜肽治療藥物的生產複雜性與生物利用度問題
  • 市場區隔分析
    • 技術：在複雜勝胜肽的合成中更多地使用固相方法
    • 藥物類別：1 型和 2 型糖尿病患者對胰島素調節葡萄糖代謝的需求增加
    • 給藥途徑：在急性醫院護理環境中，由於即時和有效性，擴大採用靜脈注射
    • 應用：擴大胜肽療法在心血管疾病的應用，模擬內源性胜肽參與血壓調節的作用
    • 最終使用者：擴大胜肽療法在醫院和診所的使用，以解決和管理病患病情
    • 製造類型：由於需要專業製造能力和快速擴大生產規模的能力，增加了 CMO 的招聘
  • 市場趨勢分析
    • 擴大藥品研發活動並增加政府投資以加強美洲的醫療領域
    • 亞太地區對先進研究設施和技術的大量公共和私人投資
    • 加強胜肽製造能力，開拓新的應用領域以及主要參與企業在歐洲、中東和非洲的存在
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章勝胜肽治療市場：依技術分類

  • 介紹
  • 混合相
  • 液相
  • 固相

第7章勝胜肽治療市場：依藥物類別

  • 介紹
  • 促腎上腺皮質激素
  • 抑鈣素
  • 胰島素
  • 亮丙瑞林
  • Octreotide
  • 加壓素

第8章勝胜肽治療市場：依給藥途徑

  • 介紹
  • 靜脈注射
  • 鼻/肺給藥
  • 口服給藥
  • 經皮

第9章勝胜肽治療市場：依應用分類

  • 介紹
  • 心血管疾病
  • 胃腸道疾病
  • 感染疾病
  • 神經系統疾病
  • 腫瘤學

第10章勝胜肽治療市場：依最終用戶分類

  • 介紹
  • 醫院/診所
  • 長期照護設施
  • 實驗室

第11章按製造類型胜肽治療市場

  • 介紹
  • 合約製造組織
  • 公司內部

第12章美洲勝胜肽治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太勝胜肽治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲勝胜肽治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析

第16章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-030EE4851583

[196 Pages Report] The Peptide Therapeutics Market size was estimated at USD 33.06 billion in 2023 and expected to reach USD 35.76 billion in 2024, at a CAGR 8.35% to reach USD 57.97 billion by 2030.

Peptide therapeutics use short chains of amino acids to treat or control various diseases and medical conditions. These biologically active molecules possess unique properties, making them an efficient drug development and pharmaceutical research option. The surging prevalence of chronic diseases, including cancer and diabetes, is raising the need for effective treatment options and an improved understanding of protein-protein interactions leading to targeted therapies. The growing investment in research & development activities and a robust clinical pipeline with therapeutic candidates result in novel peptide therapeutics being developed. However, the inherent instability of peptides and the high cost of manufacturing peptides may adversely impact the development of peptide therapeutics. Moreover, recent developments in drug delivery systems and the development of new peptides are expected to expand the potential applications for peptides.

KEY MARKET STATISTICS
Base Year [2023] USD 33.06 billion
Estimated Year [2024] USD 35.76 billion
Forecast Year [2030] USD 57.97 billion
CAGR (%) 8.35%

Technology: Rising utilization of solid phase approach for synthesis of complex peptides

The hybrid phase approach combines liquid-phase and solid-phase synthesis features to enhance efficiency and scalability while maintaining high purity levels for peptide production. This technique is favored while developing complex or large peptides due to its ability to overcome challenges associated with traditional methods. Liquid phase peptide synthesis (LPPS) involves coupling amino acids in solution using various chemical reactions. LPPS is suitable for small-scale production of short to medium-length peptides due to its relatively fast reaction rates compared to solid-phase methods. Solid phase peptide synthesis (SPPS) involves attaching the first amino acid to a solid resin support, followed by the sequential addition of subsequent amino acids. This method is widely preferred due to its ability to synthesize longer and more complex peptides and ease of purification and scalability. Hybrid phase technology is preferred for developing large or complex peptides due to its combined advantages from liquid and solid phases. Liquid phase synthesis is primarily used for small-scale, short- to medium-length peptide production. Solid-phase peptide synthesis is widely favored due to its versatility in synthesizing longer and more complex peptides while offering easy purification and scalability options.

Drug Class: Increasing need for insulin to regulate glucose metabolism for type 1 and type 2 diabetes

Adrenocorticotropic hormone (ACTH) is a polypeptide hormone secreted and produced by the anterior pituitary gland. Therapeutically, ACTH is utilized in managing certain disorders where there is a need to stimulate cortisol production. This includes treatment for conditions such as adrenal insufficiency and certain inflammatory disorders that respond to increased cortisol levels. The exogenous form used in therapy provides a direct stimulus to the adrenal cortex by simulating the action of occurring ACTH, encouraging it to secrete cortisol, thereby exerting anti-inflammatory and immunostimulatory effects. Calcitonin is critical in calcium and phosphorus metabolism. It is produced in humans primarily by the parafollicular thyroid gland cells. Therapeutic forms of calcitonin, derived from salmon or synthetically produced, are utilized primarily in treating postmenopausal osteoporosis, Paget's disease, and hypercalcemia. By inhibiting osteoclast activity, calcitonin reduces bone resorption, thereby decreasing blood calcium levels. Insulin is a fundamental peptide hormone critical for regulating glucose metabolism produced by the beta cells of the pancreas, facilitating glucose uptake from the blood into the muscle, liver, and fat cells. In the therapeutic context, insulin is vital in managing diabetes mellitus, both type 1 and type 2, where the body's ability to produce or respond to insulin is impaired. Leuprorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH) and functions as a potent inhibitor of gonadotropin secretion when used in continuous administration. It is employed in the treatment of hormone-responsive cancers such as prostate cancer in men and endometriosis and uterine fibroids in women. Octreotide is a synthetic octapeptide analog of the natural hormone somatostatin, possessing similar but longer-lasting pharmacological effects. It is primarily used in the management of acromegaly, a condition characterized by excess production of growth hormone, and in the control of symptoms caused by certain types of tumors that secrete hormones, such as carcinoid tumors and vasoactive intestinal peptide-secreting adenomas (VIPomas). Octreotide works by inhibiting the secretion of various hormones, including growth hormone, gastrin, insulin, and glucagon. Vasopressin, also referred to as antidiuretic hormone (ADH), is a peptide hormone that is secreted by the posterior pituitary gland and produced by the hypothalamus. ADH is critical in regulating the body's water retention by increasing water reabsorption in the kidney's collecting ducts. In a therapeutic setting, vasopressin and its analogs are used to treat diabetes insipidus, a condition characterized by excess thirst and the production of large amounts of diluted urine, and for managing variceal bleeding due to its vasoconstrictive properties.

Route of Administration: Rising adoption of intravenous administration due to peptide therapeutics immediacy and effectiveness in acute hospital care settings

Intravenous (IV) administration of peptide therapeutics ensures direct delivery into the bloodstream, facilitating immediate bioavailability. This route is particularly advantageous for peptides that are poorly absorbed through the gastrointestinal tract or extensively metabolized when administered by other routes. IV administration is critical for peptides used in acute care settings or where rapid onset of action is necessary. However, it requires clinical infrastructure and skilled personnel to administer, potentially limiting its applicability to outpatient settings or chronic treatments. Nasal & pulmonary routes offer non-invasive administration alternatives for peptide therapeutics, capable of providing efficient absorption and immediate action for certain conditions. Nasal administration is particularly suited for peptides targeting the central nervous system, leveraging the nose-to-brain pathway. Pulmonary administration is ideal for peptides intended for respiratory ailments, allowing direct delivery to the lungs. Both methods bypass first-pass metabolism, potentially increasing the therapeutic's bioavailability. Oral administration is a preferred route for drug delivery, attributed to its convenience, patient compliance, and cost-effectiveness. Peptides are subject to enzymatic degradation within the gastrointestinal tract and suffer from poor permeability across the intestinal epithelium. Advances in pharmaceutical sciences, such as enzyme inhibitors, permeation enhancers, and nanoparticle delivery systems, have shown promise in overcoming these hurdles, albeit with varying degrees of success. Transdermal delivery of peptide therapeutics offers a compelling balance between efficacy and patient compliance, eliminating the need for injections or specialized inhalation devices. This route is particularly advantageous for chronic conditions requiring sustained release of medication. Advances in transdermal technologies, including microneedles, iontophoresis, and ultrasound, have improved the transport of peptides across the skin barrier. Formulation strategies that enhance skin permeability and peptide stability are central to the successful development of transdermal peptide therapeutics.

Application: Widening use of peptide therapeutics in cardiovascular disorders to simulate the action of endogenous peptides involved in blood pressure regulation

In cardiovascular disorders, peptide therapeutics have been used for their precise mechanisms of action, which can effectively modulate vascular function, blood pressure, and coagulation pathways. Anticoagulant peptides are utilized to prevent thrombosis, a critical risk factor for myocardial infarction and stroke. In gastrointestinal (GI) disorders, peptide therapeutics present an avenue for targeted treatment options. In addition, peptides that mimic or inhibit gastrointestinal hormones can regulate motility, absorption, and secretion within the GI tract, addressing symptoms of various disorders. Their targeted action can aid in managing conditions stemming from hormonal imbalances or disruptions in GI-related disorders. Peptide therapeutics bring a novel approach to managing infectious disorders, especially in an era of increasing antibiotic resistance. Antimicrobial peptides (AMPs) offer a broad-spectrum antimicrobial activity, targeting bacteria, fungi, and even some viruses by disrupting their cellular membranes. Their mode of action reduces the likelihood of resistance development, making them crucial contenders in the fight against drug-resistant infections. In neurological disorders, peptide therapeutics are being explored for their potential for crossing the blood-brain barrier (BBB) and delivering neuroprotective effects directly to the central nervous system (CNS). Peptides target specific neurotransmitter systems, providing opportunities for the treatment of diseases, including Alzheimer's, Parkinson's, and multiple sclerosis. In oncology, peptide therapeutics represent a fast-growing area, with peptides being investigated for their anti-cancer properties, including direct cytotoxic effects on cancer cells, inhibition of angiogenesis, and vehicles for targeted drug delivery. Tumor-homing peptides are able to selectively deliver chemotherapeutic agents or radionuclides to tumor cells, minimizing damage to healthy tissues and enhancing treatment efficacy.

End User: Expanding the use of peptide therapeutics in hospitals and clinics to address and manage patient conditions

In hospitals & clinics, peptide therapeutics are primarily utilized for direct patient care. They are employed in treating numerous conditions, including cancer, metabolic disorders, cardiovascular diseases, and infectious diseases. Peptide drugs offer a targeted approach to treatment due to their high specificity and potency with relatively low toxicity, allowing for higher efficacy with potentially fewer side effects compared to traditional small molecule drugs. Their application in hospitals & clinics continuously evolves with advances in peptide engineering and drug delivery technologies, enhancing their effectiveness and patient compliance. Long-term care facilities prioritize treatments that ensure the well-being of patients over extended periods, often focusing on management rather than cure. Peptide therapeutics used in long-term care facilities need to have minimal side effects and require less frequent dosing schedules to accommodate the caregiving environment. Research laboratories are crucial in the early stages of peptide therapeutic development. Researchers focus on identifying new bioactive peptides, elucidating their mechanisms of action, and optimizing their properties for therapeutic use. This involves cutting-edge molecular biology, biochemistry, and pharmacology techniques to design, synthesize, and assess the activity of peptide candidates.

Manufacturing Type: Increasing adoption of CMOs owing to the need for specialized manufacturing capabilities and the ability to scale production rapidly

Contract manufacturing organizations provide essential services in the production of peptide therapeutics, serving pharmaceutical and biotech companies that either do not possess the necessary in-house production facilities or choose to outsource manufacturing to focus on core competencies. CMOs offer various services, from synthesizing peptides in small quantities for research purposes to large-scale production for commercial use. They possess the technical expertise, advanced technologies, and regulatory knowledge required for the efficient and compliant manufacture of peptide therapeutics. In-house production refers to the scenario where pharmaceutical or biotechnology companies have the facilities and resources to manufacture peptide therapeutics. This approach allows companies to maintain direct control over the production processes, quality control, and supply chain management, potentially reducing risks associated with reliance on external suppliers. Large pharmaceutical companies often establish in-house production facilities with the financial resources to invest in the necessary infrastructure and skilled personnel. This model facilitates closer integration between research and development activities and manufacturing, which can be advantageous in rapidly evolving therapeutic areas.

Regional Insights

The peptide therapeutics market is evolving in the Americas due to well-established pharmaceutical industries, increased research activities, and a growing number of approved peptide drugs. Patent activity in this region is notable, with several major pharmaceutical companies headquartered in the area. In recent years, investments in innovative peptide formulations have increased, indicating a robust market potential for new therapeutic approaches. The rising prevalence of chronic disease, improving healthcare infrastructure, and growing awareness regarding peptide therapeutics are encouraging the growth of the peptide therapeutics market in the APAC region. In addition, ongoing advancements and the development of efficient, scalable, and cost-effective synthetic strategies for producing peptides are anticipated to encourage the adoption of peptide therapeutics globally. The peptide therapeutics market is developing in the EMEA region owing to the regulatory framework supporting innovation within biotechnology and funding research projects related to peptide therapeutics. The European Union demonstrates a well-established market for peptide therapeutics, supported by comprehensive healthcare systems and a high degree of awareness regarding advanced treatment options. The EU's regulatory framework, through the European Medicines Agency (EMA), has been instrumental in approving and monitoring peptide-based drugs. The peptide therapeutics market in the African region is currently growing steadily, characterized by growing research activities and increasing awareness toward advanced therapeutic options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Peptide Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Peptide Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Peptide Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AmbioPharm, Inc., Amgen Inc., Amide Technologies, Inc., AstraZeneca PLC, Bachem Holding AG, Biosynth Ltd., Bristol Myers Squibb Company, Cidara Therapeutics, Inc., Corden Pharma International GmbH, Cybrexa, Inc., Eccogene, Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ipsen Group, IRBM S.p.A., Ironwood Pharmaceuticals, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Peptidream Co., Ltd., Perpetual Medicines Corporation, Pfizer Inc., Piramal Pharma Limited, PolyPeptide Group AG, RELIEF THERAPEUTICS Holding SA, Sanofi S.A., Sanyou Biopharmaceuticals Co., Ltd., Shanghai Full-Life Technologies Co, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, WuXi AppTec Co., Ltd., and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Peptide Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Hybrid Phase
    • Liquid Phase
    • Solid Phase
  • Drug Class
    • Adrenocorticotropic Hormone
    • Calcitonin
    • Insulin
    • Leuprorelin
    • Octreotide
    • Vasopressin
  • Route of Administration
    • Intravenous Administration
    • Nasal & Pulmonary Administration
    • Oral Administration
    • Transdermal Administration
  • Application
    • Cardiovascular Disorders
    • Gastrointestinal Disorders
    • Infectious Disorders
    • Neurological Disorders
    • Oncology
  • End User
    • Hospitals & Clinics
    • Long-term Care Facilities
    • Research Laboratories
  • Manufacturing Type
    • Contract Manufacturing Organization
    • In-house
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • Indiana
        • Maryland
        • Massachusetts
        • Minnesota
        • New Jersey
        • New York
        • North Carolina
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Peptide Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Peptide Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Peptide Therapeutics Market?

4. What is the market share of the leading vendors in the Peptide Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Peptide Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for effective therapeutic options
      • 5.1.1.2. Exponential use of peptides in aesthetic dermatology
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse recalls of peptide therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities for new peptide development worldwide
      • 5.1.3.2. Shift toward personalized medicine and identification of peptide biomarkers
    • 5.1.4. Challenges
      • 5.1.4.1. Production complexity and bioavailability issues of peptide therapeutics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Rising utilization of solid phase approach for synthesis of complex peptides
    • 5.2.2. Drug Class: Increasing need for insulin to regulate glucose metabolism for type 1 and type 2 diabetes
    • 5.2.3. Route of Administration: Rising adoption of intravenous administration due to peptide therapeutics immediacy and effectiveness in acute hospital care settings
    • 5.2.4. Application: Widening use of peptide therapeutics in cardiovascular disorders to simulate the action of endogenous peptides involved in blood pressure regulation
    • 5.2.5. End User: Expanding the use of peptide therapeutics in hospitals and clinics to address and manage patient conditions
    • 5.2.6. Manufacturing Type: Increasing adoption of CMOs owing to the need for specialized manufacturing capabilities and the ability to scale production rapidly
  • 5.3. Market Trend Analysis
    • 5.3.1. Expanding pharmaceutical R&D activities and growing government investment to strengthen the healthcare sector in the Americas
    • 5.3.2. Significant public and private investment in advanced research facilities and technologies in the Asia-Pacific region
    • 5.3.3. Enhancement in peptide manufacturing capabilities, exploring new application areas, and presence of major players in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Peptide Therapeutics Market, by Technology

  • 6.1. Introduction
  • 6.2. Hybrid Phase
  • 6.3. Liquid Phase
  • 6.4. Solid Phase

7. Peptide Therapeutics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Adrenocorticotropic Hormone
  • 7.3. Calcitonin
  • 7.4. Insulin
  • 7.5. Leuprorelin
  • 7.6. Octreotide
  • 7.7. Vasopressin

8. Peptide Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous Administration
  • 8.3. Nasal & Pulmonary Administration
  • 8.4. Oral Administration
  • 8.5. Transdermal Administration

9. Peptide Therapeutics Market, by Application

  • 9.1. Introduction
  • 9.2. Cardiovascular Disorders
  • 9.3. Gastrointestinal Disorders
  • 9.4. Infectious Disorders
  • 9.5. Neurological Disorders
  • 9.6. Oncology

10. Peptide Therapeutics Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals & Clinics
  • 10.3. Long-term Care Facilities
  • 10.4. Research Laboratories

11. Peptide Therapeutics Market, by Manufacturing Type

  • 11.1. Introduction
  • 11.2. Contract Manufacturing Organization
  • 11.3. In-house

12. Americas Peptide Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Peptide Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Peptide Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Expansion of GMP Capacities at CordenPharma Frankfurt: Elevating Early-Phase Peptide API Manufacturing
    • 15.3.2. Revolutionizing Peptide Therapeutics: Orbis Medicines Innovates for Oral Drug Delivery
    • 15.3.3. Expanding Facilities in Peptide Therapeutic Production: WuXi AppTec's Strategic Growth
    • 15.3.4. Glenmark Pharmaceuticals Announces Biosimilar Liraglutide Launch in India to Revolutionize Anti-Diabetic Treatment
    • 15.3.5. Amide Technologies' Novel Manufacturing Platform and Strategic Capital Advancement
    • 15.3.6. Strategic Acquisition Elevates Pharmathen's Position in the Peptide Therapeutics Market
    • 15.3.7. Biosynth Solidifies Market Position with Strategic Acquisition of Pepceuticals
    • 15.3.8. Strategic Collaboration between PeptiDream and Genentech to Advance Peptide-Radioisotope Therapeutics
    • 15.3.9. Merck and IRBM Forge Forward in Peptide Therapeutics: A Partnership to Expand and Innovate in Biopharmaceuticals
    • 15.3.10. Fujitsu Launches Pioneering Bio-Drug Design Accelerator Focused on Advancing Peptide Therapeutics in Cancer and CNS Regeneration
    • 15.3.11. Comprehensive Support for Peptide Therapeutics Development from Conception to Manufacturing for Introducing SynCrest's CRDMO Service

16. Competitive Portfolio

  • 16.1. Key Company Profiles
  • 16.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PEPTIDE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PEPTIDE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PEPTIDE THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2023 VS 2030 (%)
  • FIGURE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 22. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 27. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 28. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PEPTIDE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LEUPRORELIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LEUPRORELIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NASAL & PULMONARY ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NASAL & PULMONARY ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 104. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 116. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 128. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 156. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 168. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 180. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 192. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 204. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 216. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 228. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 240. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 264. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 276. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 288. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 313. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 314. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 315. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 316. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 317. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 318. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 319. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 320. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 321. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 322. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 323. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 326. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 327. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 328. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 329. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 330. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 331. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 332. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 333. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 334. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)

TABLE